Personalized Immunotherapy

To attack 30 unique targets found by AI/ML in each patient.
First in industry: mass spectrometry per patient for AI training.

Died Annually


Colorectal cancer is the second most deadly cancer, after lung cancer, in America.
Late-Stage Chemo Failures May Find Hope In BreakBio's Treatment.

Breakthrough Technology

Our mission is a breakthrough in the treatment and cure of all solid cancers. BreakBio is named for this vision a Breakthrough in Biotech. Our first aim is to quickly achieve Breakthrough Therapy Designation from the FDA for our first cancer indication.

BreakBio’s proprietary

BreakBio’s proprietary, patent-pending AI/ML designed personalized cancer vaccines are for all solid cancers, with the first trial in metastatic colorectal cancer starting in 2024.

Watch Video

BreakBio's Recognition

BreakBio CEO Roy de Souza was honored by the American Cancer Society at an event on May 11, 2023.

Roy de Souza, CEO, Breakbio, shares his story of loss to cancer, and his passion for finding a breakthrough in cancer care.


Cancer vaccine tailor made for each patient.

Treatment is in two parts


Cancer vaccine to create

  • BreakBio AI analyzes cancer cells from each patient to find not one, but many proteins on them
  • AI training repeated for patient from innovative, unique mass spectrometry analysis of each patient's cancer cells
    • Dawn of AI drug design per patient
  • BreakBio manufactures the drugs: synthetic copies of these proteins, the dawn of personalized drug manufacture

Colorectal cancer drugs
that help T-cells infiltrate tumors

Reduces barriers to immune system and Slows rate of growth of cancer cells

Select targets that are related to mutated genes and targets related to non mutated genes, so can benefit both patients with a high or low number of mutations (Tumor Mutational Burden, TMB) in their cancer.

Press Release

Recent Developments and
Press Releases

Watch video

BreakBio Colon Cancer Vaccine


Interesting articles updated
every daily